Case Study: Access after drug withdrawal

A leading biotech firm had an approved oncology drug for B-cell CLL, which was also in clinical trials for other indications. The firm planned to launch the same drug for a neurological disorder under a different treatment regimen. It withdrew the oncology medicine from global markets to prepare for its re-launch under a different dosage for the new indication. However, they wanted to ensure ongoing access for oncology patients who lacked alternate options.

Read the case study to learn how the ongoing program gave access to 10,000 patients globally on a named-patient basis where there was a clear unmet medical need.